Stratified analyses of genome wide association study data reveal haplotypes for a candidate gene on chromosome 2 (KIAA1211L) is associated with opioid use in patients of Arabian descent.
GWAS, stratification
Haplotypes
KIAA1211L
Opioid use disorder
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
31 01 2020
31 01 2020
Historique:
received:
13
02
2019
accepted:
30
12
2019
entrez:
2
2
2020
pubmed:
2
2
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Genome Wide Association Studies (GWAS) have been conducted to identify genes and pathways involved in development of opioid use disorder. This study extends the first GWAS of substance use disorder (SUD) patients from the United Arab Emirates (UAE) by stratifying the study group based on opioid use, which is the most common substance of use in this cohort. The GWAS cohort consisted of 512 (262 case, 250 controls) male participants from the UAE. The samples were genotyped using the Illumina Omni5 Exome system. Data was stratified according to opioid use using PLINK. Haplotype analysis was conducted using Haploview 4.2. Two main associations were identified in this study. Firstly, two SNPs on chromosome 7 were associated with opioid use disorder, rs118129027 (p-value = 1.23 × 10 This is the first GWAS to identify candidate genes associated with opioid use disorder in participants from the UAE. The lack of other genetic data of Arabian descent opioid use patients has hindered replication of the findings. Nevertheless, the outcomes implicate new pathways in opioid use disorder that requires further research to assess the role of the identified genes in the development of opioid use disorder.
Sections du résumé
BACKGROUND
Genome Wide Association Studies (GWAS) have been conducted to identify genes and pathways involved in development of opioid use disorder. This study extends the first GWAS of substance use disorder (SUD) patients from the United Arab Emirates (UAE) by stratifying the study group based on opioid use, which is the most common substance of use in this cohort.
METHODS
The GWAS cohort consisted of 512 (262 case, 250 controls) male participants from the UAE. The samples were genotyped using the Illumina Omni5 Exome system. Data was stratified according to opioid use using PLINK. Haplotype analysis was conducted using Haploview 4.2.
RESULTS
Two main associations were identified in this study. Firstly, two SNPs on chromosome 7 were associated with opioid use disorder, rs118129027 (p-value = 1.23 × 10
CONCLUSION
This is the first GWAS to identify candidate genes associated with opioid use disorder in participants from the UAE. The lack of other genetic data of Arabian descent opioid use patients has hindered replication of the findings. Nevertheless, the outcomes implicate new pathways in opioid use disorder that requires further research to assess the role of the identified genes in the development of opioid use disorder.
Identifiants
pubmed: 32005204
doi: 10.1186/s12888-019-2425-8
pii: 10.1186/s12888-019-2425-8
pmc: PMC6995052
doi:
Substances chimiques
CRACD protein, human
0
Microfilament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Subventions
Organisme : National Rehabilitation Center (UAE)
ID : 2013/1
Pays : International
Références
Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1179-88
pubmed: 20468071
Drug Alcohol Depend. 1998 Nov 1;52(3):231-41
pubmed: 9839149
Eur J Pain. 2014 Oct;18(9):1343-51
pubmed: 24756859
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7501-6
pubmed: 19416921
Hum Mol Genet. 2012 Aug 1;21(15):3345-55
pubmed: 22543972
JAMA Psychiatry. 2013 Mar;70(3):325-33
pubmed: 23303482
BJPsych Int. 2017 Nov 01;14(4):92-96
pubmed: 29093960
Mol Psychiatry. 2016 May;21(5):608-14
pubmed: 26239289
Am J Med Genet B Neuropsychiatr Genet. 2019 Jan;180(1):68-79
pubmed: 30556296
Regul Toxicol Pharmacol. 2015 Dec;73(3):999-1004
pubmed: 26382614
Twin Res Hum Genet. 2014 Apr;17(2):108-20
pubmed: 24556202
ScientificWorldJournal. 2013;2013:748979
pubmed: 23533358
Clin Med Insights Oncol. 2016 Mar 14;10:5-15
pubmed: 26997880
Neuron. 2011 Feb 24;69(4):618-27
pubmed: 21338875
Psychiatr Genet. 2010 Oct;20(5):207-14
pubmed: 20520587
Neuropsychopharmacology. 2015 Mar;40(4):1016-26
pubmed: 25345593
Lancet Oncol. 2008 Mar;9(3):257-68
pubmed: 18308251
Genome Res. 2013 Sep;23(9):1395-409
pubmed: 23657883
Am J Psychiatry. 2003 Apr;160(4):687-95
pubmed: 12668357
Mol Psychiatry. 2014 Jan;19(1):55-62
pubmed: 23183491
Pain Physician. 2012 Jul;15(3 Suppl):ES9-38
pubmed: 22786464
Subst Abuse Treat Prev Policy. 2016 May 13;11(1):19
pubmed: 27177422
Nat Methods. 2011 Sep 04;8(10):833-5
pubmed: 21892150
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
Eur J Hum Genet. 2016 Aug;24(8):1202-5
pubmed: 26733288
JAMA. 1997 Mar 19;277(11):925-6
pubmed: 9062334
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Lancet. 2012 Jan 7;379(9810):17-8
pubmed: 22232799
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
Eur J Pain. 2015 Jan;19(1):59-66
pubmed: 24807782
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
Am J Med Genet A. 2015 Nov;167A(11):2664-73
pubmed: 26227573
Neuropsychobiology. 2014;69(1):19-24
pubmed: 24401326
Biol Psychiatry. 2014 Jul 1;76(1):66-74
pubmed: 24143882